Advancing MPN Genomic Profiling with an Amplicon-Based Myeloid NGS Panel

Unlock the Future of MPN Diagnostics

Myeloproliferative neoplasms (MPNs) are a group of myeloid malignancies characterized by excessive production of mature myeloid cells in the blood. Traditionally, labs use sequential single gene testing (SGT) to evaluate somatic mutations in three driver genes (JAK2, MPL, CALR), then pivot to next-generation sequencing (NGS) if no mutations are found. However, this method is becoming inefficient as the list of clinically significant biomarkers increases.

In this webinar, Dr. Krishnamurthy will share her experience with an amplicon-based myeloid NGS panel for comprehensive genomic profiling of MPNs. It provides a comprehensive assessment of driver genes (JAK2, MPL, CALR, CSF3R) and other MPN-related genes with important prognostic and therapeutic implications.

She will compare the myeloid NGS panel to the traditional PCR-based sequential SGT, highlighting the benefits and limitations of both approaches. Additionally, she will emphasize the need to reassess traditional testing approaches to improve diagnostic accuracy, prognostic evaluation, and therapeutic strategies.

Learning Objectives

1. Describe the molecular profiling of MPN, including classification and biomarkers implicated in the diagnosis, prognosis, and therapeutic selection for MPN patients
2. Assess traditional sequential single genes testing via PCR in identifying driver genes
3. Evaluate clinical scenarios where an amplicon-based myeloid NGS panel identified critical co-mutations of clinical significance
4. Investigate a proposed diagnostic algorithm that integrates both PCR and NGS for detecting very low variant allele frequencies (VAF) in driver genes

Fisher Healthcare is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.™ Program. One P.A.C.E.™ credit-hour will be provided for this complimentary basic level program.